Naslov
MicroRNAs in prostate cancerR – (pre)analytical challenges

Autori
Dobrović, Irena ; Ulamec, Monika ; Sinčić, Nino

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Book of abstracts : HDBMB2019 : crossroads in life sciences / Katalinić, Maja ; Dulić, Morana ; Stuparević, Igor - Zagreb : Hrvatsko Društvo za Biotehnologiju, 2019, 79-79

ISBN
978-953-95551-7-5

Skup
Congress of the Croatian Society of Biochemistry and Molecular Biology "Crossroads in Life Sciences" (HDBMB2019)

Mjesto i datum
Lovran, Hrvatska, 25.09.2019. - 28.09.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
miRNAs ; prostate cancer ; liquid biopsy ; biomarkers

Sažetak
Prostate cancer (PCa) represents a most commonly diagnosed neoplasm among men of all ages, with incidence rates steadily rising. However, there is a need for more sophisticated biomarkers for diagnosis, prognosis and management. MicroRNAs (miRNAs) in liquid biopsies and tissue have emerged as potential biomarkers for PCa that could help better distinguish aggressive vs. non-aggressive tumors, and malignant vs. non-malignant conditions. However, conflicting data was reported for certain miRNAs and published papers often lack certain information which is necessary to contextualize the results. With growing body of evidence, questions are being raised regarding diverse (pre)analytical factors that influence miRNA analysis. In order to analyze and address current problems in miRNA clinical research on PCa, a PubMed-based literature search was conducted with the last update in May 2019. The following (pre)analytical factors influencing miRNA analysis were studied and compared across the studies: control groups, serum and plasma comparison, sample storage, quality control steps, data normalization, etc. By examining published papers, we propose these steps for conducting future research: 1) control groups should be age-matched, preferably benign prostate hyperplasia patients ; 2) sample collection and handling should be explained in detail: sample timing, centrifugation, hemolysis monitoring, storage conditions ; 3) plasma and serum samples should be stored at -80° C up to 5 years before analysis, while FFPE blocks up to 10 years and data adjusted according to block’s age ; 5) both endogenous and exogenous miRNAs should be used for quality control ; 6) miRNAs dysregulated in PCa should be avoided for data normalization, and MIQE guidelines adhered when publishing RT-qPCR results. Studying miRNAs in PCa is a dynamic field with a growing amount of published data. There is a lack of consistency and reproducibility, largely due to a missing consensus on preferred sample collection, sample handling, RNA extraction and miRNA analysis. Other aspects such as different control groups and sample storage also influence variable results obtained in miRNA research. In order to be able to compare studies and come closer to translating miRNA into clinical use, it is necessary to come up with guidelines for sample collection, storage, and processing, and for data analysis within different platforms.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA